The role of CXCL13 as a potential importance in CRC therapy has been confirmed by other investigators, who also revealed that CXCL13/CXCR5 axis may target tumors by recruiting B lymphocytes, and is essential in the anti-tumor immune response of TME in CRC [109,116]. The gene discussed is CXCR5; the disease is neoplasm.